Endocrine Abstracts

Growth hormone-releasing hormone (GHRH), apart from stimulating GH secretion in the pituitary, exerts many extrapituitary functions, including stimulation of cell proliferation and survival. GHRH and its receptor splice variants (SVs) are expressed in different cancer cell types, where they modulate cell growth. It has been shown that GHRH antagonists exert anticancer activities in a variety of tumors, including malignant pleural mesothelioma and lung cancer, one of the leadin...

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the formation of amyloid-β (Aβ) plaques and Tau neurofibrillary tangles, leading to neuronal loss, inflammation, reduced neurogenesis, and cognitive impairment. Currently, there is no effective cure for AD, highlighting the urgent need for novel therapeutic strategies. Growth hormone-releasing hormone (GHRH), besides promoting the release of pituitary growth hormone (GH), exerts many perip...

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETscan be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resectionis the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are pr...

Growth hormone-releasing hormone (GHRH), apart from stimulating GH secretion in the pituitary, exerts many peripheral functions, including stimulation of cell proliferation and survival. In fact, GHRH and GHRH receptors (GHRH-Rs) are expressed in different cancer cell types, where they promote proliferation and survival. Conversely, GHRH antagonists exert antineoplastic activities in several tumors, including lung cancer, one of the leading causes of death by cancer worldwide....

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH). Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are preferre...